Tirzepatide dosing & administration
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous injection: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Titration schedule
2.5 mg
Frequency
Once weekly
Duration
First 4 weeks
FDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
5-10 mg
Frequency
Once weekly
Duration
Increase by 2.5 mg after at least 4 weeks at each dose
Per FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
Timing
Best time to take
Pick any day of the week that works for you and stick with it. Many people choose a weekend day so they can rest if they experience mild nausea. The exact time of day doesn't matter much thanks to the long half-life—just be consistent [5][6].
With food?
Tirzepatide injections can be taken with or without food—it won't affect how the medication works. However, because it slows stomach emptying significantly, eating smaller meals will help you avoid nausea and discomfort. Avoid large, fatty meals.
If stacking
Tirzepatide is typically used as a standalone weight management therapy. If you have diabetes and take insulin or sulfonylureas, those doses will likely need to be reduced to prevent low blood sugar. [5][6] Always coordinate with your healthcare provider before combining medications.
Adjusting your dose
Increase if
- You've tolerated the current dose for 4+ weeks without significant GI problems
- Weight loss has slowed or plateaued and you haven't reached the maximum dose
- Blood sugar targets aren't being met (for diabetes patients)
- Your healthcare provider recommends continuing the titration schedule
Decrease if
- Nausea, vomiting, or diarrhea are severe and don't improve after a few weeks
- You're unable to eat enough to maintain basic nutrition
- You experience signs of dehydration from persistent GI symptoms
- Side effects significantly impact your daily life and functioning
Signs of right dose
- Steady weight loss of 1-2+ pounds per week
- Feeling genuinely satisfied with smaller portions
- Reduced food cravings and less thinking about food
- Minimal or manageable GI side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—the pen makes it quick and virtually painless, and you can easily do it yourself at home
Best sites
Storage
Before reconstitution
Store new, unopened pens in the refrigerator at 36-46°F (2-8°C). Never freeze tirzepatide—freezing destroys the medication. Keep pens in the original carton to protect from light. If needed, unopened pens can be stored at room temperature (up to 86°F/30°C) for up to 21 days.
After reconstitution
Tirzepatide pens are single-use and do not require reconstitution. Once you use a pen, dispose of it properly in a sharps container. Never reuse pens or attempt to get multiple doses from one pen.
Signs of degradation — discard the vial
Sample daily schedule
Same day each week (e.g., every Sunday morning)
As prescribed (2.5mg to 15mg depending on titration phase) injection
Site: Rotate between abdomen, thigh, and arm weekly
Pick a day you'll consistently remember—many people choose weekends so they can rest if needed. The injection takes under a minute once you're comfortable with it. If you miss a dose and it's been less than 4 days, take it as soon as you remember. If more than 4 days have passed, skip it and take your next dose on the regular day.
Safety
Is it safe?
Side effects
Commonly reported: Nausea, Diarrhea, Decreased Appetite, Vomiting
Less common: Gallbladder Problems, Hair Thinning (Telogen Effluvium)
Stop and seek help if
- Severe or persistent GI symptoms that prevent adequate nutrition despite dose adjustments and supportive care
- Signs of pancreatitis—severe abdominal pain radiating to the back requiring emergency evaluation
- Allergic reaction—rash, hives, itching, facial swelling, or difficulty breathing
- Signs of thyroid problems—neck lump, persistent hoarseness, difficulty swallowing
- Pregnancy or planning to become pregnant (stop at least 1 month before attempting conception)
- Severe kidney problems or persistent dehydration from GI symptoms
- Your healthcare provider recommends discontinuation for any reason
Tirzepatide is a prescription medication that should only be started, adjusted, or stopped under medical supervision. This information is for education only and does not replace professional medical advice. While stopping tirzepatide abruptly is generally safe, discuss any changes with your healthcare provider. Weight regain is common after discontinuation.
Flagged pairings
- Semaglutide and other GLP-1 agonists — Never combine GLP-1 medications—they work through overlapping mechanisms. Combining would dramatically increase side effects without additional benefit.
- Insulin — Tirzepatide dramatically enhances insulin's blood sugar-lowering effect. Insulin doses typically need reduction of 20-50% or more when starting tirzepatide to prevent dangerous hypoglycemia. Close monitoring essential.
- Sulfonylureas (glipizide, glyburide, glimepiride) — High hypoglycemia risk when combined. Sulfonylurea doses usually need significant reduction. Monitor blood sugar frequently and watch for symptoms of low blood sugar.
Published research
What the studies show
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · 2022
This landmark trial proved tirzepatide's extraordinary effectiveness for weight loss. Participants on the 15mg dose lost an average of 20.9% of their body weight over 72 weeks—about 52 pounds. Over half the participants lost more than 20% of their weight, results previously only achievable with surgery.
Frías JP, Davies MJ, Rosenstock J, et al. · 2021
Head-to-head comparison showed tirzepatide beat semaglutide at every dose level. The 15mg tirzepatide dose reduced HbA1c by 2.30 percentage points versus 1.86 with semaglutide. Weight loss was also significantly greater—5.5kg more weight lost with tirzepatide 15mg compared to semaglutide 1mg.
Wadden TA, Chao AM, Machineni S, et al. · 2023
For people who had already lost at least 5% of their weight through intensive lifestyle changes, adding tirzepatide produced an additional 18.4% weight loss over 72 weeks. Total weight loss from original starting weight exceeded 25% for many participants.
Wilson JM, Lin Y, Luo MJ, et al. · 2022
Comprehensive analysis showed tirzepatide improves virtually every cardiovascular risk factor: blood pressure dropped 6-9 mmHg, triglycerides fell 25%, LDL cholesterol decreased, and inflammatory markers improved significantly across all doses studied.
Eli Lilly and Company · 2025
Eli Lilly and Company · 2026
US label for the obesity and obstructive sleep apnea indications. Boxed warning for rodent thyroid C-cell tumors and contraindication in personal or family history of MTC or MEN 2. Dose escalation from 2.5 mg once weekly in 2.5 mg steps at intervals of at least 4 weeks, maximum 15 mg once weekly, any time of day with or without meals. Adverse reactions in the pooled weight-reduction trials (5/10/15 mg): nausea 25/29/28%, diarrhea 19/21/23%, vomiting 8/11/13%, hair loss 5/4/5%; cholelithiasis 1.1%, cholecystitis 0.7%, cholecystectomy 0.2%; adjudicated acute pancreatitis 0.2%. Hair loss and gallbladder events were associated with weight reduction. Elimination half-life approximately 5-6 days; tirzepatide delays gastric emptying, largest after the first dose.
Aronne LJ, Sattar N, Horn DB, et al. · 2024
After a 36-week open-label lead-in producing 20.9% mean weight reduction, participants switched to placebo regained 14.0% of body weight over the following 52 weeks, while those continuing tirzepatide lost a further 5.5%.
Look M, Dunn JP, Kushner RF, et al. · 2025
DXA substudy of 160 SURMOUNT-1 participants. At week 72 body weight fell 21.3%, fat mass 33.9% and lean mass 10.9% with tirzepatide. Of the body weight lost, approximately 75% was fat mass and 25% was lean mass, in both the tirzepatide and placebo groups.
Coskun T, Sloop KW, Loghin C, et al. · 2018
The discovery paper for tirzepatide. A fatty-acid-modified peptide with dual GIP and GLP-1 receptor agonist activity engineered for once-weekly subcutaneous dosing. In mice it reduced body weight and food intake significantly more than a GLP-1 receptor agonist. The most frequent human side effects in phase 1 were gastrointestinal (vomiting, nausea, decreased appetite, diarrhoea, abdominal distension), all dose-dependent.
Willard FS, Douros JD, Gabe MBN, et al. · 2020
Receptor occupancy analysis at clinically efficacious doses shows a greater degree of engagement at the GIP receptor than the GLP-1 receptor, an imbalanced mechanism of action. Tirzepatide mimics native GIP at the GIP receptor but is biased at the GLP-1 receptor toward cAMP generation over beta-arrestin recruitment, with weaker GLP-1 receptor internalisation.
Heise T, DeVries JH, Urva S, et al. · 2023
Secondary analysis of a randomised, double-blind study of tirzepatide 15 mg, semaglutide 1 mg and placebo at 28 weeks. Tirzepatide significantly reduced body weight versus both placebo and semaglutide with greater fat mass reduction, and significantly reduced appetite versus placebo.
Bjerre Knudsen L, Madsen LW, Andersen S, et al. · 2010
The GLP-1 receptor was localised to rodent thyroid C-cells, where agonists stimulated calcitonin release and C-cell hyperplasia. Humans and cynomolgus monkeys had low GLP-1 receptor expression in thyroid C-cells and agonists did not generate calcitonin release in primates, delineating species-specific differences in thyroid GLP-1 receptor expression and action.
Pasternak B, Wintzell V, Hviid A, et al. · 2024
Cohort of 145,410 GLP-1 receptor agonist users versus 291,667 DPP-4 inhibitor users across Denmark, Norway and Sweden, 2007-2021. GLP-1 receptor agonist use was not associated with an increased risk of thyroid cancer (hazard ratio 0.93, 95% CI 0.66 to 1.31) over a mean 3.9 years of follow-up; hazard ratio for medullary thyroid cancer 1.19 (0.37 to 3.86).
Zhang Q, Delessa CT, Augustin R, et al. · 2021
GIP receptors in hypothalamic feeding centres mediate control of food intake and body weight. Acyl-GIP increased cFos neuronal activity in hypothalamic feeding centres and lowered body weight and food intake in wild-type but not CNS-Gipr knockout mice, and the superior metabolic effect of GLP-1/GIP co-agonism over GLP-1 alone was extinguished in CNS-Gipr knockout mice.
Samms RJ, Christe ME, Collins KA, et al. · 2021
Tirzepatide improved insulin sensitivity in obese mice to a greater extent than GLP-1 receptor agonism, and did so in the absence of GLP-1R-mediated weight loss by enhancing glucose disposal in white adipose tissue. A long-acting GIP receptor agonist reproduced the effect, showing GIP receptor agonism contributes insulin sensitisation and adipose tissue glucose handling.
Eli Lilly and Company / ClinicalTrials.gov · 2020
Phase 3 cardiovascular outcomes trial of tirzepatide versus dulaglutide in 13,299 participants with type 2 diabetes and increased cardiovascular risk, assessing major adverse cardiovascular events. Started 29 May 2020.
He Z, Gao Y, Lieu L, et al. · 2019
GLP-1 receptor agonism directly activates arcuate POMC neurons and indirectly inhibits NPY/AgRP neurons through increased GABAergic inhibitory input, the two arcuate pathways through which GLP-1 receptor activation reduces food intake.
Head to head
Tirzepatide compared
Studied for
Conditions Tirzepatide has been researched in
Want the full picture?
The complete Tirzepatide research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.